Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bart A Ploeger

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Journal of Pharmacological and Toxicological Methods|January 3, 2013
Predicting human exposure of active drug after oral prodrug administration, using a joined in vitro/in silico-in vivo extrapolation and physiologically-based pharmacokinetic modeling approachJonas Malmborg, Bart A Ploeger
Drug Discovery Today|May 14, 2013
The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal livesTjerk Bueters, Bart A Ploeger, Sandra A G Visser
Drug Metabolism and Pharmacokinetics|March 3, 2009
Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelingBart A Ploeger, Piet H van der Graaf, Meindert Danhof
Journal of Pharmacokinetics and Pharmacodynamics|January 17, 2008
Extensions to the visual predictive check to facilitate model performance evaluationTeun M Post, Jan I Freijer, Bart A Ploeger, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 27, 2014
Translational pharmacokinetic modeling of fingolimod (FTY720) as a paradigm compound subject to sphingosine kinase-mediated phosphorylationNelleke Snelder, Bart A Ploeger, Olivier Luttringer, et al.
Journal of Clinical Pharmacology|December 8, 2016
Model-Based Dose Selection for Intravaginal Ring Formulations Releasing Anastrozole and Levonorgestrel Intended for the Treatment of Endometriosis SymptomsIsabel Reinecke, Marcus-Hillert Schultze-Mosgau, Rüdiger Nave, et al.
Bulletin of Mathematical Biology|October 7, 2006
Application of the convection-dispersion equation to modelling oral drug absorptionJan I Freijer, Teun M Post, Bart A Ploeger, et al.
Clinical Pharmacokinetics|September 27, 2021
Clinical Pharmacokinetics and Pharmacodynamics of the Selective Progesterone Receptor Modulator Vilaprisan: A Comprehensive OverviewMarcus-Hillert Schultze-Mosgau, Bart A Ploeger, Matthias Frei, et al.
British Journal of Clinical Pharmacology|May 3, 2020
Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intakeAnne Keunecke, Sven Hoefman, Henk-Jan Drenth, et al.
Journal of Clinical Pharmacology|February 28, 2013
Evaluation of the impact of UGT polymorphism on the pharmacokinetics and pharmacodynamics of the novel PPAR agonist sipoglitazarFrances Stringer, Bart A Ploeger, Joost DeJongh, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Journal of Pharmacological and Toxicological Methods|January 3, 2013
Predicting human exposure of active drug after oral prodrug administration, using a joined in vitro/in silico-in vivo extrapolation and physiologically-based pharmacokinetic modeling approachJonas Malmborg, Bart A Ploeger
Drug Discovery Today|May 14, 2013
The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal livesTjerk Bueters, Bart A Ploeger, Sandra A G Visser
Drug Metabolism and Pharmacokinetics|March 3, 2009
Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelingBart A Ploeger, Piet H van der Graaf, Meindert Danhof
Journal of Pharmacokinetics and Pharmacodynamics|January 17, 2008
Extensions to the visual predictive check to facilitate model performance evaluationTeun M Post, Jan I Freijer, Bart A Ploeger, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 27, 2014
Translational pharmacokinetic modeling of fingolimod (FTY720) as a paradigm compound subject to sphingosine kinase-mediated phosphorylationNelleke Snelder, Bart A Ploeger, Olivier Luttringer, et al.
Journal of Clinical Pharmacology|December 8, 2016
Model-Based Dose Selection for Intravaginal Ring Formulations Releasing Anastrozole and Levonorgestrel Intended for the Treatment of Endometriosis SymptomsIsabel Reinecke, Marcus-Hillert Schultze-Mosgau, Rüdiger Nave, et al.
Bulletin of Mathematical Biology|October 7, 2006
Application of the convection-dispersion equation to modelling oral drug absorptionJan I Freijer, Teun M Post, Bart A Ploeger, et al.
Clinical Pharmacokinetics|September 27, 2021
Clinical Pharmacokinetics and Pharmacodynamics of the Selective Progesterone Receptor Modulator Vilaprisan: A Comprehensive OverviewMarcus-Hillert Schultze-Mosgau, Bart A Ploeger, Matthias Frei, et al.
British Journal of Clinical Pharmacology|May 3, 2020
Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intakeAnne Keunecke, Sven Hoefman, Henk-Jan Drenth, et al.
Journal of Clinical Pharmacology|February 28, 2013
Evaluation of the impact of UGT polymorphism on the pharmacokinetics and pharmacodynamics of the novel PPAR agonist sipoglitazarFrances Stringer, Bart A Ploeger, Joost DeJongh, et al.
Pageof 4